Technical Analysis for FUSN - Fusion Pharmaceuticals Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Resistance | Bearish | 100.38% | |
New Uptrend | Bullish | 100.38% | |
Pocket Pivot | Bullish Swing Setup | 100.38% | |
Bullish Engulfing | Bullish | 113.41% | |
Earnings Movers | Other | 113.41% | |
Multiple of Ten Bearish | Other | 113.41% | |
Wide Bands | Range Expansion | 113.41% | |
Oversold Stochastic | Weakness | 113.41% | |
Narrow Range Bar | Range Contraction | 128.27% | |
Earnings Movers | Other | 128.27% |
Alert | Time |
---|---|
Possible Pocket Pivot | 10 days ago |
Up 1 ATR | 10 days ago |
Rose Above 50 DMA | 10 days ago |
60 Minute Opening Range Breakout | 10 days ago |
50 DMA Resistance | 10 days ago |
Get a Trading Assistant
- Earnings date: 05/09/2024
Fusion Pharmaceuticals Inc. Description
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Clinical Development Antibodies Tumor Cell Biology Insulin Precision Medicine Tyrosine Kinase Receptors Bladder Cancer Checkpoint Inhibitor Proteins Fibroblast Growth Factor Fibroblast Growth Factor Receptor Radiopharmaceuticals Growth Factor Pharmacodynamics
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 21.44 |
52 Week Low | 2.31 |
Average Volume | 2,395,405 |
200-Day Moving Average | 6.48 |
50-Day Moving Average | 12.63 |
20-Day Moving Average | 14.57 |
10-Day Moving Average | 19.04 |
Average True Range | 0.98 |
RSI (14) | 83.39 |
ADX | 48.18 |
+DI | 56.86 |
-DI | 9.42 |
Chandelier Exit (Long, 3 ATRs) | 18.50 |
Chandelier Exit (Short, 3 ATRs) | 12.03 |
Upper Bollinger Bands | 25.50 |
Lower Bollinger Band | 3.65 |
Percent B (%b) | 0.81 |
BandWidth | 149.96 |
MACD Line | 2.87 |
MACD Signal Line | 1.97 |
MACD Histogram | 0.8972 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 21.50 | ||||
Resistance 3 (R3) | 21.50 | 21.43 | 21.47 | ||
Resistance 2 (R2) | 21.43 | 21.39 | 21.44 | 21.46 | |
Resistance 1 (R1) | 21.38 | 21.36 | 21.41 | 21.38 | 21.45 |
Pivot Point | 21.31 | 21.31 | 21.33 | 21.32 | 21.31 |
Support 1 (S1) | 21.26 | 21.27 | 21.29 | 21.26 | 21.19 |
Support 2 (S2) | 21.19 | 21.24 | 21.20 | 21.18 | |
Support 3 (S3) | 21.14 | 21.19 | 21.17 | ||
Support 4 (S4) | 21.14 |